This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
29 Oct 2012

Bluebird awarded funding for trials of LentiGlobin

A gene therapy developer has received funding for trials of its new treatment for beta-thalassmia.

 

Gene therapy specialist bluebird bio has been awarded $9.3 million (£5.7 million) to support a Phase 1/2 study into the safety and effectiveness of LentiGlobin, the company's developmental treatment for beta-thalassemia.
 

Related News